8-K: Liquidia Clears Legal Hurdle for YUTREPIA Launch, Begins Commercial Shipments for PAH and PH-ILD Treatment

Liquidia Corporation announced that a U.S. District Court denied United Therapeutics' motion for a preliminary injunction, clearing the path for the immediate commercial launch and first shipment of its FDA-approved YUTREPIA (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Summary

• Liquidia Corporation announced that the U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation's (UTHR) motion for a preliminary injunction and temporary restraining order.
• The lawsuit, filed by UTHR on May 9, 2025, alleged infringement of U.S. Patent No. 11,357,782 and sought to prevent Liquidia from commercializing YUTREPIA.
• The Court denied UTHR's request, in part, based on its conclusion that UTHR is not likely to succeed on the merits of its claims.
• This denial removes any pending motions seeking emergency relief to enjoin the launch of YUTREPIA.
• The U.S. Food and Drug Administration (FDA) granted approval of YUTREPIA for the treatment of PAH and PH-ILD on May 23, 2025.
• Liquidia is scheduled to make its first commercial shipment of YUTREPIA on June 2, 2025, making it available to be prescribed to patients via specialty pharmacies.
• YUTREPIA is an inhaled dry-powder formulation of treprostinil, designed using Liquidia's PRINT technology for enhanced lung deposition.
• PAH affects an estimated 45,000 patients in the U.S., while PH-ILD affects over 60,000 patients.
• Liquidia has also filed a motion to dismiss, stay, or transfer UTHR's claims regarding the '782 patent, which remains pending.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the successful denial of a critical preliminary injunction, which clears the path for the immediate commercial launch of a newly FDA-approved product, YUTREPIA. This legal victory and rapid commercialization represent significant milestones for the company.

Positives

• The U.S. District Court denied United Therapeutics' motion for a preliminary injunction and temporary restraining order, removing a significant legal barrier to commercialization.
• The Court's denial was based, in part, on its conclusion that United Therapeutics is not likely to succeed on the merits of its claims.
• YUTREPIA received FDA approval for both PAH and PH-ILD on May 23, 2025.
• Liquidia demonstrated exceptional speed by scheduling the first commercial shipment of YUTREPIA just five business days after FDA approval.
• YUTREPIA offers a new and differentiated therapeutic alternative for patients with PAH and PH-ILD, delivered via a convenient, low-effort, palm-sized device.
• The company's sales force has already begun promotion, and the product has been listed with compendia, indicating readiness for market penetration.

Negatives

• The underlying lawsuit filed by United Therapeutics Corporation against Liquidia Corporation regarding patent infringement is still ongoing, despite the denial of the preliminary injunction.
• There remains a risk that commercialization of YUTREPIA may be blocked or delayed in connection with future legal proceedings, or Liquidia may be required to pay damages, including royalties, as a result of these legal proceedings.

Risks

• Ongoing Legal Proceedings: Despite the denial of the preliminary injunction, the lawsuit filed by United Therapeutics Corporation (UTHR) against Liquidia Corporation alleging infringement of U.S. Patent No. 11,357,782 is not concluded and its final outcome is uncertain.
• Potential for Future Injunctions or Damages: It is possible that commercialization of YUTREPIA may be blocked or delayed in connection with future legal proceedings, or Liquidia may be required to pay damages, including royalties, in connection with its commercial launch.
• Competitive Environment: The company operates in a very competitive and rapidly changing environment, and the industry has inherent risks that could affect the commercial potential for YUTREPIA.
• Uncertainty of Market Acceptance: There is a risk regarding the acceptance by the market of YUTREPIA, its potential pricing, and/or reimbursement by third-party payors, and whether such acceptance is sufficient to support continued commercialization.
• Inability to Predict All Risks: Management cannot predict all risks, nor assess the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from forward-looking statements.

Future Outlook

Liquidia aims to position YUTREPIA as the prostacyclin of first choice for patients with PAH and PH-ILD, following its rapid commercial launch. The company anticipates continued commercialization efforts and market penetration for YUTREPIA, while also developing L606 and marketing generic Treprostinil Injection.

Management Comments

• Dr. Roger Jeffs, CEO of Liquidia, stated: "We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace."
• Dr. Jeffs also noted: "In just over one week, our sales force hit the ground running with the promotion of YUTREPIA, the product was listed with compendia, and commercial product was shipped to specialty pharmacies."
• Dr. Jeffs emphasized: "This extraordinary pace is a direct result of our rigorous preparation and the strategic urgency driving our desire to provide patients immediate access to the unique attributes of YUTREPIA as we look to position it as the prostacyclin of first choice for patients with PAH and PH-ILD."

Industry Context

Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease affecting an estimated 45,000 patients in the U.S., with no cure, and treatments focused on symptom alleviation, functional improvement, and delaying progression. Pulmonary hypertension associated with interstitial lung disease (PH-ILD) affects over 60,000 patients in the U.S., with any level of PH in ILD patients associated with poor 3-year survival. YUTREPIA enters this market as a new inhaled treprostinil option, offering a differentiated therapeutic alternative for these underserved patient populations.

Legal Proceedings

• On May 9, 2025, United Therapeutics Corporation (UTHR) filed a motion for preliminary injunction and temporary restraining order against Liquidia Corporation in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368).
• UTHR's complaint alleged infringement of U.S. Patent No. 11,357,782 and sought to enjoin Liquidia from commercializing YUTREPIA.
• On May 30, 2025, the U.S. District Court denied UTHR's motion for preliminary injunction and temporary restraining order, concluding that UTHR is not likely to succeed on the merits of its claims.
• This denial means UTHR no longer has any motions pending that seek emergency relief to enjoin the launch of YUTREPIA.
• Liquidia has filed a motion to dismiss, stay, or transfer UTHR's claims regarding the '782 patent, which remains pending with the Court.
• The denial of the preliminary injunction does not conclude the lawsuit, and it is possible that commercialization of YUTREPIA may still be blocked or delayed in connection with future legal proceedings, or Liquidia may be required to pay damages, including royalties.

Stakeholder Impact

• Shareholders: The denial of the preliminary injunction significantly de-risks the commercialization of YUTREPIA, potentially leading to increased revenue and market value for Liquidia.
• Patients: Patients suffering from PAH and PH-ILD will gain immediate access to a new, differentiated therapeutic option, YUTREPIA, which could improve their treatment outcomes and quality of life.
• Competitors (United Therapeutics): The court's decision is a setback for United Therapeutics' efforts to block YUTREPIA's market entry, intensifying competition in the treprostinil market.
• Employees: The successful launch and commercialization of YUTREPIA could lead to job security and potential growth opportunities within Liquidia.

Next Steps

• Liquidia will proceed with the full commercial launch of YUTREPIA, with the first commercial shipment scheduled for June 2, 2025.
• The company's sales force will continue promotion of YUTREPIA to healthcare providers.
• Liquidia will continue to pursue its motion to dismiss, stay, or transfer United Therapeutics' claims regarding the '782 patent, which remains pending with the Court.
• Liquidia will continue to develop L606, an investigational sustained-release formulation of treprostinil.

Key Dates

Recommendation

Keywords

Liquidia Corporation, YUTREPIA, treprostinil, pulmonary arterial hypertension, PAH, pulmonary hypertension associated with interstitial lung disease, PH-ILD, FDA approval, preliminary injunction, patent infringement, commercial launch, rare disease, biopharmaceutical, PRINT technology, United Therapeutics